No intervention would be taken
OtherNo intervention would be taken
NCT Number: NCT05214274
This multicenter registry study aims to understand the status of diagnosis and treatment, quality of life, medical costs and unmet medical needs of adult patients with chronic hypoparathyroidism in China.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Peking Union Medical College Hospital, Beijing, Beijing Municipality, China
Hypoparathyroidism (HP) is a rare (orphan) endocrine disease with low calcium and inappropriately low circulating parathyroid hormone levels, most often in adults secondary to thyroid surgery. The present study contains four parts.
The first part is a multicenter registry study. According to our predefined search criteria determined through pilot study, all patients admitted between June 1, 2020 and May 31, 2021 will be searched from the hospital information system and patients diagnosed with HP and those with suspected HP will be retrieved. The diagnosis of all or a random sample of these patients will be reviewed by endocrinologists through medical records. Patients with a confirmed diagnosis of chronic HP will served as the study population of the first part of the study.
The second part is a multicenter hospital-based survey, to investigate the missed diagnosis, quality of life, medical costs, medical experience and unmet medical needs in adult patients with chronic HP. All local patients with definite chronic HP and those with suspected HP will be invited to participate in the hospital on-site investigation. Among them, suspected HP patients need to first undergo necessary examinations to confirm the diagnosis of HP.
The third part is the verification of the reliability and validity of two quality of life scales, the Short-Form Six-Dimension version 2 (SF-6Dv2) scale and Hypoparathyroidism Patient Experience Scale (HPES). The first 100 patients with chronic HP who participate in the on-site investigation in the Peking Union Medical College Hospital will be invited.
The fourth part is a survey on physicians about the unmet need of chronic HP. All endocrinologists from each site will be invited to take part in the survey.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
This study consists of four parts, the eligibility criteria of each part is described below:
Part 1:
Search criteria of chronic HP:
Inclusion criteria
Exclusion criteria
Search criteria of suspected HP:
Inclusion criteria
Exclusion criteria
Diagnosis of chronic HP:
Inclusion criteria
Part 2
Inclusion criteria
Exclusion criteria
Part 3
Inclusion criteria
Part 4
Inclusion criteria
No intervention would be taken
Time frame: 0 day (cross-sectional)
HP is classified into postsurgical and non-postsurgical HP.
Time frame: 0 day (cross-sectional)
The most common symptoms of HP include tetany, seizures, laryngospasm, numbness, blood in the urine, renal colic and vision loss.
Time frame: 0 day (cross-sectional)
Including the situation at the time of diagnosis and the current situation
Time frame: 0 day (cross-sectional)
Including the situation at the time of diagnosis and the current situation
Time frame: 0 day (cross-sectional)
Including the situation at the time of diagnosis and the current situation
Time frame: 0 day (cross-sectional)
The situation at the time of diagnosis
Time frame: 0 day (cross-sectional)
Including the situation at the time of diagnosis and the current situation
Time frame: 0 day (cross-sectional)
First-visit reason was excerpted from previous medical records
Time frame: 0 day (cross-sectional)
First-visit department was excerpted from previous medical records
Time frame: 0 day (cross-sectional)
Number of patients diagnosed with chronic HP / Total number of outpatients and inpatients during the year
Time frame: 0 day (cross-sectional)
Number of patients receiving any kind of HP treatment/ Total number of patients diagnosed with chronic HP
Time frame: 0 day (cross-sectional)
HP treatment targets defined as normal blood calcium levels or/+ normal urine calcium level
Time frame: 0 day (cross-sectional)
Number of patients with complications / Total number of patients with chronic HP
Time frame: 0 day (cross-sectional)
Patients with missed diagnosis of chronic HP / Total number of patients with chronic HP
Time frame: 0 day (cross-sectional)
Misdiagnosis experience of HP is defined as patients with chronic HP were previously diagnosed with other diseases due to related symptoms or hypocalcemia.
Time frame: 0 day (cross-sectional)
Medical costs contains of direct medical costs and indirect medical costs
Time frame: 0 day (cross-sectional)
The SF-6Dv2 score ranges from 0.29 to 1, with higher scores indicating better performance.
Time frame: 0 day (cross-sectional)
The HPES score ranges from 0 to 100, with lower scores indicating better performance.
Time frame: 0 day (cross-sectional)
Unmet medical needs for HP treatment and quality of life by patients and physicians
Peking University
Other
The Status of Diagnosis and Treatment of Chronic Hypoparathyroidism in Chinese Adults: a Multicenter Registry Study
Acronym: PaTHwayR
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05239221
Chronic Hypoparathyroidism
Budapest, Hungary
View Trial DetailsNCT02910466
Chronic Hypoparathyroidism, Endocrine System Diseases
New York, United States
View Trial DetailsNCT03425747
Calcium Metabolism Disorders, Chronic Hypoparathyroidism
Roma, Italy
View Trial DetailsNCT07707479
Cardiovascular Diseases, Chronic Hypoparathyroidism
Athens, Greece
View Trial Details